MX363950B - Derivados de urea utiles como inhibidores de quinasa. - Google Patents
Derivados de urea utiles como inhibidores de quinasa.Info
- Publication number
- MX363950B MX363950B MX2015013945A MX2015013945A MX363950B MX 363950 B MX363950 B MX 363950B MX 2015013945 A MX2015013945 A MX 2015013945A MX 2015013945 A MX2015013945 A MX 2015013945A MX 363950 B MX363950 B MX 363950B
- Authority
- MX
- Mexico
- Prior art keywords
- kinase inhibitors
- urea derivatives
- derivatives useful
- members
- inflammatory diseases
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/44—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton
- C07C317/48—Sulfones; Sulfoxides having sulfone or sulfoxide groups and carboxyl groups bound to the same carbon skeleton the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C317/00—Sulfones; Sulfoxides
- C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
- C07C317/28—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to acyclic carbon atoms of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
- C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Se proporcionan compuestos de fórmula I, (ver Fórmula) en donde R1A R1E, R2 a R5, L y X1 a X3 tienen los significados dados en la descripción, que los compuestos tienen actividad antiinflamatoria (por ejemplo, a través de la inhibición de uno o más de los miembros de: la familia de enzimas de proteína quinasa activadas por mitógeno p38; quinasa Syk; y los miembros de la familia Src de tirosina quinasas) y tienen uso en terapia, que incluyen combinaciones farmacéuticas, especialmente en el tratamiento de enfermedades inflamatorias, incluyendo enfermedades inflamatorias del pulmón, ojo e intestinos.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201305945A GB201305945D0 (en) | 2013-04-02 | 2013-04-02 | New compounds |
GBGB1322678.2A GB201322678D0 (en) | 2013-12-20 | 2013-12-20 | New compounds |
GB201402647A GB201402647D0 (en) | 2014-02-14 | 2014-02-14 | New compounds |
PCT/GB2014/051022 WO2014162126A1 (en) | 2013-04-02 | 2014-04-01 | Urea derivatives useful as kinase inhibitors |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2015013945A MX2015013945A (es) | 2015-12-11 |
MX363950B true MX363950B (es) | 2019-04-08 |
Family
ID=50434228
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013945A MX363950B (es) | 2013-04-02 | 2014-04-01 | Derivados de urea utiles como inhibidores de quinasa. |
MX2015013944A MX363949B (es) | 2013-04-02 | 2014-04-01 | Inhibidor de quinasa. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015013944A MX363949B (es) | 2013-04-02 | 2014-04-01 | Inhibidor de quinasa. |
Country Status (14)
Country | Link |
---|---|
US (5) | US8927563B2 (es) |
EP (2) | EP2981535B8 (es) |
JP (2) | JP6495238B2 (es) |
KR (3) | KR102340654B1 (es) |
CN (2) | CN105246884B (es) |
AU (2) | AU2014246870C1 (es) |
BR (2) | BR112015024671A2 (es) |
CA (1) | CA2907663A1 (es) |
DK (2) | DK2981535T3 (es) |
EA (2) | EA030483B1 (es) |
ES (2) | ES2904277T3 (es) |
MX (2) | MX363950B (es) |
TW (1) | TWI641592B (es) |
WO (2) | WO2014162122A1 (es) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009077766A1 (en) | 2007-12-19 | 2009-06-25 | Cancer Research Technology Limited | Pyrido[2,3-b]pyrazine-8-substituted compounds and their use |
ES2469367T3 (es) | 2010-02-01 | 2014-06-18 | Cancer Research Technology Limited | 1-(5-Terc-butil-2-fenil-2H-pirazol-3-il)-3-[2-fluoro-4-(1-metil-2-oxo-2,3-dihidro-1H-imidazo[4,5-b]piridin-7-iloxi)-fenil]-urea y compuestos relacionados y su uso en terapia |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
PL2763984T3 (pl) | 2011-10-03 | 2016-10-31 | 1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP | |
GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
WO2014162121A1 (en) | 2013-04-02 | 2014-10-09 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
CN105246884B (zh) * | 2013-04-02 | 2018-05-22 | 瑞斯比维特有限公司 | 用作激酶抑制剂的脲衍生物 |
GB201320729D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
GB201320732D0 (en) | 2013-11-25 | 2014-01-08 | Cancer Rec Tech Ltd | Methods of chemical synthesis |
CA2934199A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
TWI751099B (zh) | 2014-02-14 | 2022-01-01 | 英商瑞斯比維特有限公司 | 作為激酶抑制劑之吡唑基脲,包含其之製藥組成物及其用途 |
MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
AR107165A1 (es) | 2015-12-23 | 2018-03-28 | Chiesi Farm Spa | Inhibidores de quinasa |
CN109071505B (zh) * | 2016-04-06 | 2021-11-16 | 奥苏拉收购有限公司 | 激酶抑制剂 |
LT3691620T (lt) | 2017-10-05 | 2022-09-26 | Fulcrum Therapeutics, Inc. | P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui |
US10342786B2 (en) | 2017-10-05 | 2019-07-09 | Fulcrum Therapeutics, Inc. | P38 kinase inhibitors reduce DUX4 and downstream gene expression for the treatment of FSHD |
CN110878055B (zh) * | 2018-09-06 | 2021-02-05 | 中国科学院化学研究所 | 一种制备羰基杂环类化合物的方法 |
Family Cites Families (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2290520C (en) | 1997-05-23 | 2009-01-27 | Bayer Corporation | Inhibition of p38 kinase activity by aryl ureas |
JP2001521934A (ja) | 1997-11-03 | 2001-11-13 | ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド | 抗炎症薬としての芳香族ヘテロ環式化合物 |
EP1140840B1 (en) | 1999-01-13 | 2006-03-22 | Bayer Pharmaceuticals Corp. | -g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors |
EP2298311B1 (en) | 1999-01-13 | 2012-05-09 | Bayer HealthCare LLC | w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors |
UA73492C2 (en) | 1999-01-19 | 2005-08-15 | Aromatic heterocyclic compounds as antiinflammatory agents | |
EP1165516B1 (en) | 1999-03-12 | 2004-10-06 | Boehringer Ingelheim Pharmaceuticals Inc. | Heterocyclic urea and related compounds useful as anti-inflammatory agents |
ATE312823T1 (de) | 1999-07-09 | 2005-12-15 | Boehringer Ingelheim Pharma | Verfahren zur herstellung heteroarylsubstituierter ureaverbindungen |
CA2389360C (en) | 1999-11-16 | 2008-06-03 | Steffen Breitfelder | Urea derivatives as anti-inflammatory agents |
US6492529B1 (en) | 2000-01-18 | 2002-12-10 | Boehringer Ingelheim Pharmaceuticals, Inc. | Bis pyrazole-1H-pyrazole intermediates and their synthesis |
US6525046B1 (en) | 2000-01-18 | 2003-02-25 | Boehringer Ingelheim Pharmaceuticals, Inc. | Aromatic heterocyclic compounds as antiinflammatory agents |
CA2443697A1 (en) | 2001-04-13 | 2002-10-24 | Pier F. Cirillo | 1,4-disubstituted benzo-fused compounds |
EP1381594A1 (en) | 2001-04-13 | 2004-01-21 | Boehringer Ingelheim Pharmaceuticals Inc. | Urea compounds useful as anti-inflammatory agents |
CA2445003A1 (en) | 2001-05-16 | 2002-11-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Diarylurea derivatives useful as anti-inflammatory agents |
CA2448626A1 (en) | 2001-05-25 | 2002-12-05 | Boehringer Ingelheim Pharmaceuticals, Inc. | Carbamate and oxamide compounds as inhibitors of cytokine production |
DE60219793T2 (de) | 2001-07-11 | 2008-01-24 | Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield | Verfahren zur Behandlung von Cytokin-Vermittelten Erkrankungen |
WO2003068228A1 (en) | 2002-02-11 | 2003-08-21 | Bayer Pharmaceuticals Corporation | Aryl ureas with angiogenesis inhibiting activity |
AU2003210969A1 (en) | 2002-02-11 | 2003-09-04 | Bayer Corporation | Aryl ureas with raf kinase and angiogenesis inhibiting activity |
US7041669B2 (en) | 2002-02-25 | 2006-05-09 | Boehringer Ingelheim Pharmaceuticals, Inc. | 1,4-benzofused urea compounds useful in treating cytokine mediated diseases |
TW200406374A (en) | 2002-05-29 | 2004-05-01 | Novartis Ag | Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases |
CA2494824A1 (en) | 2002-08-08 | 2004-02-19 | Boehringer Ingelheim Pharmaceuticals, Inc. | Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes |
US20050014753A1 (en) | 2003-04-04 | 2005-01-20 | Irm Llc | Novel compounds and compositions as protein kinase inhibitors |
WO2004113352A1 (en) | 2003-06-19 | 2004-12-29 | Amedis Pharmaceuticals Ltd. | Silylated heterocyclylurea derivatives as cytokine-inhibitors |
CA2530776A1 (en) | 2003-06-30 | 2005-01-20 | Boehringer Ingelheim Pharmaceuticals, Inc. | Process of making di-aryl urea compounds |
US20050148555A1 (en) | 2003-08-22 | 2005-07-07 | Boehringer Ingelheim Pharmaceuticals, Inc. | Methods of treating COPD and pulmonary hypertension |
MXPA06002853A (es) | 2003-09-11 | 2006-06-14 | Kemia Inc | Inhibidores citoquina. |
WO2005044825A1 (en) | 2003-10-21 | 2005-05-19 | Amedis Pharmaceuticals Ltd. | Silicon compounds and their use |
EP1689376A2 (en) | 2003-11-28 | 2006-08-16 | Novartis AG | Diaryl urea derivatives in the treatment of protein kinase dependent diseases |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
GB0423554D0 (en) | 2004-10-22 | 2004-11-24 | Cancer Rec Tech Ltd | Therapeutic compounds |
TW200740820A (en) | 2005-07-05 | 2007-11-01 | Takeda Pharmaceuticals Co | Fused heterocyclic derivatives and use thereof |
TWI325423B (en) | 2005-10-28 | 2010-06-01 | Lilly Co Eli | Kinase inhibitors |
US7790756B2 (en) | 2006-10-11 | 2010-09-07 | Deciphera Pharmaceuticals, Llc | Kinase inhibitors useful for the treatment of myleoproliferative diseases and other proliferative diseases |
GB0818033D0 (en) | 2008-10-02 | 2008-11-05 | Respivert Ltd | Novel compound |
KR20110070887A (ko) | 2008-10-02 | 2011-06-24 | 레스피버트 리미티드 | P38 엠에이피 키나제 억제제 |
KR20110094130A (ko) | 2008-12-11 | 2011-08-19 | 레스피버트 리미티드 | P38 map 키나제 억제제 |
GB0905955D0 (en) | 2009-04-06 | 2009-05-20 | Respivert Ltd | Novel compounds |
TWI624457B (zh) * | 2009-06-10 | 2018-05-21 | 中外製藥股份有限公司 | 四環性化合物 |
GB0921731D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Theraputic uses |
GB0921730D0 (en) | 2009-12-11 | 2010-01-27 | Respivert Ltd | Method of treatment |
CN103864657A (zh) | 2010-03-15 | 2014-06-18 | 宇部兴产株式会社 | 制备酰胺化合物的方法 |
GB201005589D0 (en) | 2010-04-01 | 2010-05-19 | Respivert Ltd | Novel compounds |
JP5787977B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | P38mapキナーゼ阻害剤 |
JP5787976B2 (ja) | 2010-04-08 | 2015-09-30 | レスピバート・リミテツド | P38mapキナーゼ阻害剤としてのピラゾリルウレア |
GB201009731D0 (en) * | 2010-06-10 | 2010-07-21 | Pulmagen Therapeutics Inflamma | Kinase inhibitors |
GB201010193D0 (en) | 2010-06-17 | 2010-07-21 | Respivert Ltd | Medicinal use |
WO2011158044A2 (en) | 2010-06-17 | 2011-12-22 | Respivert Limited | Respiratory formulations and compounds for use therein |
GB201010196D0 (en) * | 2010-06-17 | 2010-07-21 | Respivert Ltd | Methods |
WO2012044090A2 (ko) * | 2010-09-29 | 2012-04-05 | 크리스탈지노믹스(주) | 단백질 키나제 억제 활성을 갖는 신규한 아미노퀴나졸린 화합물 |
EP2578582A1 (en) | 2011-10-03 | 2013-04-10 | Respivert Limited | 1-Pyrazolyl-3-(4-((2-anilinopyrimidin-4-yl)oxy)napththalen-1-yl)ureas as p38 MAP kinase inhibitors |
PL2763984T3 (pl) | 2011-10-03 | 2016-10-31 | 1-pirazolilo-3-(4-((2-anilinopirymidyno-4-ilo)oksy)naftaleno-1-ilo)moczniki jako inhibitory kinazy p38 MAP | |
KR101994381B1 (ko) | 2011-12-09 | 2019-06-28 | 키에시 파르마슈티시 엣스. 피. 에이. | 키나아제 억제제 |
GB201214750D0 (en) | 2012-08-17 | 2012-10-03 | Respivert Ltd | Compounds |
WO2014033447A2 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
GB201215357D0 (en) | 2012-08-29 | 2012-10-10 | Respivert Ltd | Compounds |
WO2014033446A1 (en) | 2012-08-29 | 2014-03-06 | Respivert Limited | Kinase inhibitors |
US9783556B2 (en) | 2012-08-29 | 2017-10-10 | Respivert Limited | Kinase inhibitors |
US9732063B2 (en) | 2012-11-16 | 2017-08-15 | Respivert Limited | Kinase inhibitors |
US20160016934A1 (en) | 2013-03-14 | 2016-01-21 | Respivert Limited | Kinase inhibitors |
WO2014162121A1 (en) | 2013-04-02 | 2014-10-09 | Topivert Pharma Limited | Kinase inhibitors based upon n-alkyl pyrazoles |
CN105246884B (zh) * | 2013-04-02 | 2018-05-22 | 瑞斯比维特有限公司 | 用作激酶抑制剂的脲衍生物 |
CA2934199A1 (en) | 2013-12-20 | 2015-06-25 | Respivert Limited | Urea derivatives useful as kinase inhibitors |
TWI751099B (zh) | 2014-02-14 | 2022-01-01 | 英商瑞斯比維特有限公司 | 作為激酶抑制劑之吡唑基脲,包含其之製藥組成物及其用途 |
MA40775A (fr) | 2014-10-01 | 2017-08-08 | Respivert Ltd | Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38 |
CN109071505B (zh) * | 2016-04-06 | 2021-11-16 | 奥苏拉收购有限公司 | 激酶抑制剂 |
-
2014
- 2014-04-01 CN CN201480031484.4A patent/CN105246884B/zh not_active Expired - Fee Related
- 2014-04-01 AU AU2014246870A patent/AU2014246870C1/en not_active Ceased
- 2014-04-01 KR KR1020217023664A patent/KR102340654B1/ko active IP Right Grant
- 2014-04-01 BR BR112015024671A patent/BR112015024671A2/pt active Search and Examination
- 2014-04-01 KR KR1020157031292A patent/KR102283883B1/ko active IP Right Grant
- 2014-04-01 EP EP14716378.6A patent/EP2981535B8/en active Active
- 2014-04-01 US US14/242,531 patent/US8927563B2/en active Active
- 2014-04-01 ES ES14715106T patent/ES2904277T3/es active Active
- 2014-04-01 JP JP2016505888A patent/JP6495238B2/ja not_active Expired - Fee Related
- 2014-04-01 TW TW103112073A patent/TWI641592B/zh not_active IP Right Cessation
- 2014-04-01 ES ES14716378T patent/ES2856902T3/es active Active
- 2014-04-01 JP JP2016505887A patent/JP6464384B2/ja active Active
- 2014-04-01 WO PCT/GB2014/051018 patent/WO2014162122A1/en active Application Filing
- 2014-04-01 EA EA201591906A patent/EA030483B1/ru not_active IP Right Cessation
- 2014-04-01 DK DK14716378.6T patent/DK2981535T3/da active
- 2014-04-01 MX MX2015013945A patent/MX363950B/es active IP Right Grant
- 2014-04-01 CN CN201480031577.7A patent/CN105408315B/zh not_active Expired - Fee Related
- 2014-04-01 US US14/242,741 patent/US9481648B2/en active Active
- 2014-04-01 CA CA2907663A patent/CA2907663A1/en not_active Abandoned
- 2014-04-01 WO PCT/GB2014/051022 patent/WO2014162126A1/en active Application Filing
- 2014-04-01 DK DK14715106.2T patent/DK2981526T3/da active
- 2014-04-01 EA EA201591907A patent/EA027782B1/ru not_active IP Right Cessation
- 2014-04-01 EP EP14715106.2A patent/EP2981526B1/en active Active
- 2014-04-01 KR KR1020157031287A patent/KR102283876B1/ko active IP Right Grant
- 2014-04-01 MX MX2015013944A patent/MX363949B/es active IP Right Grant
- 2014-04-01 AU AU2014246866A patent/AU2014246866B2/en not_active Ceased
- 2014-04-01 BR BR112015024678-8A patent/BR112015024678B1/pt not_active IP Right Cessation
-
2015
- 2015-02-19 US US14/626,548 patent/US20150166483A1/en not_active Abandoned
-
2016
- 2016-09-09 US US15/261,174 patent/US9790174B2/en active Active
-
2017
- 2017-10-05 US US15/726,241 patent/US10435361B2/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015013945A (es) | Derivados de urea utiles como inhibidores de quinasa. | |
MX2017004128A (es) | Derivados de diarilurea como inhibidores de quinasa p38. | |
MX2015002044A (es) | Pirazolil-ureas como inhibidores de quinasa. | |
WO2014033447A3 (en) | Diaryl urea derivatives as p38 map kinase inhibitors | |
PH12018502125A1 (en) | Bipyrazole derivatives as jak inhibitors | |
EA201590941A1 (ru) | Гетероциклические ингибиторы глютаминазы | |
MX2015014234A (es) | Derivados 2-aminopirido-[4,3-d]pirimidin-5-ona y su uso como inhibidores de wee-1. | |
MX2014005928A (es) | Inhibidores ciclicos de glutaminasa. | |
MX2015010125A (es) | Derivados de piridazinona-amidas. | |
EA202090258A2 (ru) | ПРОИЗВОДНЫЕ ПИРРОЛО[3,2-d]ПИРИМИДИНА ДЛЯ ЛЕЧЕНИЯ ВИРУСНЫХ ИНФЕКЦИЙ И ДРУГИХ ЗАБОЛЕВАНИЙ | |
MX346336B (es) | Derivados de quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinasa. | |
EA201691032A1 (ru) | Производные изохромена в качестве ингибиторов фосфоинозитид-3-киназ | |
NZ709153A (en) | Pyrimidinone derivatives having human neutrophil elastase inhibitory activity | |
MX2014008864A (es) | Derivados de triazolo[4,5-d]pirimidina. | |
MX2012012031A (es) | Inhibidores de la actividad de la proteina tirosina quinasa y uso de los mismos para tratar transtornos oftalmicos. | |
MX2017009600A (es) | Derivados de 2-fenil-3h-imidazo[4,5-b]piridina utiles como inhibidores de actividad de receptor huerfano similar a tirosina cinasa (ror1) de tirosina cinasa de mamifero. | |
MX364859B (es) | Derivados de imidazopirazinona. | |
MX2018012275A (es) | Inhibidores de quinasa. | |
EA201650085A1 (ru) | Способ лечения опухолевого заболевания и способ селективного ингибирования роста опухолевых клеток с помощью производного хиноксалин-1,4-диоксида | |
MX369393B (es) | Derivados de ftalazina. | |
MY193381A (en) | Thiazolecarboxamides and pyridinecarboxamide compounds useful as pim kinase inhibitors | |
NZ748422A (en) | Heterocyclic glutaminase inhibitors | |
UA110978C2 (uk) | Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |